0001062993-24-010182.txt : 20240514
0001062993-24-010182.hdr.sgml : 20240514
20240514163312
ACCESSION NUMBER: 0001062993-24-010182
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240510
FILED AS OF DATE: 20240514
DATE AS OF CHANGE: 20240514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MANIAN BALA S
CENTRAL INDEX KEY: 0000941871
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38624
FILM NUMBER: 24945005
MAIL ADDRESS:
STREET 1: 1025 TERRA BELLA AVE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VACCINEX, INC.
CENTRAL INDEX KEY: 0001205922
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 161603202
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
BUSINESS PHONE: 585-271-2700
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
FORMER COMPANY:
FORMER CONFORMED NAME: VACCINEX INC
DATE OF NAME CHANGE: 20021114
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-05-10
0001205922
VACCINEX, INC.
VCNX
0000941871
MANIAN BALA S
C/O VACCINEX, INC.
1895 MOUNT HOPE AVENUE
ROCHESTER
NY
14620
1
0
0
0
0
Stock Option (Right to Buy)
1633.8
2020-05-15
Common Stock
36
36
D
Stock Option (Right to Buy)
829.5
2021-05-14
Common Stock
74
74
D
Stock Option (Right to Buy)
451.5
2022-05-11
Common Stock
136
136
D
Stock Option (Right to Buy)
235.2
2023-05-12
Common Stock
253
253
D
Stock Option (Right to Buy)
86.1
2024-05-11
Common Stock
684
684
D
Stock Option (Right to Buy)
5.75
2024-05-10
4
A
0
2685
3.96
A
2024-05-10
2034-05-10
Common Stock
2685
2685
D
Stock Option (Right to Buy)
5.75
2024-05-10
4
A
0
10108
0
A
2025-05-10
Common Stock
10108
10108
D
This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $10,625 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
All figures in this Form 4 reflect the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.
/s/ Maurice Zauderer, Attorney-in-Fact for Bala S. Manian
2024-05-14